US appeals court lets stand injunction against Roche's Mircera
This article was originally published in Scrip
Executive Summary
A US federal appeals court has let stand an injunction blocking launch of Roche's pegylated erythropoietin product Mircera (continuous erythropoietin receptor activator, CERA) because it infringes patents held by Amgen.